Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RNAC logo RNAC
Upturn stock ratingUpturn stock rating
RNAC logo

Cartesian Therapeutics Inc. (RNAC)

Upturn stock ratingUpturn stock rating
$10.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $36.43

1 Year Target Price $36.43

Analysts Price Target For last 52 week
$36.43 Target price
52w Low $8.46
Current$10.28
52w High $26.5

Analysis of Past Performance

Type Stock
Historic Profit -64.41%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 276.27M USD
Price to earnings Ratio -
1Y Target Price 36.43
Price to earnings Ratio -
1Y Target Price 36.43
Volume (30-day avg) 8
Beta 0.83
52 Weeks Range 8.46 - 26.50
Updated Date 08/28/2025
52 Weeks Range 8.46 - 26.50
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.68

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-14
When Before Market
Estimate -0.82
Actual -0.7724

Profitability

Profit Margin -
Operating Margin (TTM) -7319.13%

Management Effectiveness

Return on Assets (TTM) -13.65%
Return on Equity (TTM) -7029.26%

Valuation

Trailing PE -
Forward PE 25.45
Enterprise Value 129296696
Price to Sales(TTM) 269.27
Enterprise Value 129296696
Price to Sales(TTM) 269.27
Enterprise Value to Revenue 126.02
Enterprise Value to EBITDA -1.17
Shares Outstanding 26002000
Shares Floating 9390377
Shares Outstanding 26002000
Shares Floating 9390377
Percent Insiders 59.85
Percent Institutions 25.4

ai summary icon Upturn AI SWOT

Cartesian Therapeutics Inc.

stock logo

Company Overview

overview logo History and Background

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering RNA cell therapy for autoimmune diseases. Founded in 2016, the company focuses on engineering cells to express RNA-encoded proteins, offering a differentiated approach from traditional gene editing or viral vector-based methods. They went public through an IPO in September 2023.

business area logo Core Business Areas

  • RNA Armored Cell Therapy: Cartesian's core technology is RNA Armored Cell Therapy (rACT), which involves genetically engineering a patient's T cells with RNA to express therapeutic proteins. These engineered cells are designed to target and eliminate the underlying causes of autoimmune diseases.

leadership logo Leadership and Structure

Details about Cartesian Therapeutics' leadership team and organizational structure can be found on their investor relations website. The management team is composed of individuals with experience in cell therapy, biotechnology, and pharmaceutical development.

Top Products and Market Share

overview logo Key Offerings

  • Descartes-08: Descartes-08 is Cartesian's lead product candidate, an autologous rACT therapy being developed for the treatment of generalized myasthenia gravis (gMG). Clinical trial data is being generated. Competitors include Alexion (Soliris, Ultomiris) and Argenx (Vyvgart).
  • Descartes-30: Descartes-30 is an autologous rACT therapy designed for the treatment of relapsed or refractory multiple myeloma (r/r MM). Clinical trial data is being generated. Competitors include Bristol Myers Squibb (Abecma), Johnson & Johnson (Carvykti), and various other MM therapies.

Market Dynamics

industry overview logo Industry Overview

The cell therapy market is a rapidly growing segment of the biotechnology industry, driven by advancements in genetic engineering and immunology. The market is competitive, with numerous companies developing cell-based therapies for various diseases.

Positioning

Cartesian Therapeutics is positioning itself as a leader in RNA cell therapy, differentiating itself from competitors using gene editing or viral vector-based approaches. Their rACT platform offers potential advantages in terms of safety, efficacy, and manufacturing scalability.

Total Addressable Market (TAM)

The TAM for autoimmune disease therapies and multiple myeloma therapies are substantial, representing billions of dollars annually. Cartesian's positioning to address unmet needs in these markets with rACT positions them to capture a portion of this TAM. Estimations vary but the entire cell therapy market is expected to be around 75 billion USD by 2030.

Upturn SWOT Analysis

Strengths

  • Novel RNA cell therapy platform
  • Potential for improved safety compared to gene editing
  • Strong preclinical and early clinical data
  • Experienced management team

Weaknesses

  • Clinical stage company with no approved products
  • High cash burn rate
  • Dependence on clinical trial success
  • Manufacturing complexities of cell therapies

Opportunities

  • Expansion of rACT platform to other autoimmune diseases
  • Partnerships with pharmaceutical companies
  • Positive clinical trial results
  • Advancements in manufacturing technologies

Threats

  • Clinical trial failures
  • Competition from other cell therapy companies
  • Regulatory hurdles
  • Reimbursement challenges

Competitors and Market Share

competitor logo Key Competitors

  • ALXN
  • ARGX
  • BMY
  • JNJ

Competitive Landscape

Cartesian Therapeutics faces competition from established pharmaceutical companies and other biotechnology companies developing cell therapies. Their rACT platform offers a differentiated approach, but they need to demonstrate clinical superiority to gain market share.

Growth Trajectory and Initiatives

Historical Growth: The company's growth is primarily reflected in the advancement of its clinical pipeline and expansion of its research and development activities.

Future Projections: Future growth is dependent on the success of clinical trials, regulatory approvals, and commercialization of its rACT therapies. Analyst estimates are needed for further information. These are generally available through financial news outlets.

Recent Initiatives: Recent initiatives include progressing Descartes-08 and Descartes-30 through clinical trials, expanding the rACT platform to new disease targets, and exploring potential partnerships.

Summary

Cartesian Therapeutics is a clinical-stage biotechnology company with a novel RNA cell therapy platform targeting autoimmune diseases and multiple myeloma. The company shows promise due to its innovative approach, but is also high risk due to its dependence on clinical trial success. The firm's future hinges on positive clinical trial data and obtaining regulatory approval for its therapies. It needs to be aware of its cash burn rate, the ability to scale up its manufacturing process and the large players in its industry

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Cartesian Therapeutics Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Company Press Releases
  • Analyst Reports (if available)
  • Industry Reports (e.g., EvaluatePharma)

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share and TAM figures are estimates and may vary based on source. The information is based on publicly available data and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cartesian Therapeutics Inc.

Exchange NASDAQ
Headquaters Frederick, MD, United States
IPO Launch date 2016-06-22
President, CEO & Director Dr. Carsten Brunn Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 66
Full time employees 66

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.